Company record · QDEL · In Vitro & In Vivo Diagnostic Substances
QuidelOrtho Corp
QuidelOrtho Corp's chief financial officer on the record is Micah Young, effective July 6, 2026, per the filing record.
The record holds 1 verified CFO change for QuidelOrtho Corp from Form 8-K filings, filed June 23, 2026 and the CFO signature on its 10-K filed February 19, 2026.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled |
|---|---|
| Officer | Micah Young |
| Title as printed | Chief Financial Officer and principal financial officer |
| Basis | Latest move: transition, 8-K filed June 23, 2026 |
Seat timeline
2Every verified record for this seat, newest first, dated as the filing states it.
2026-06-23Transition
QuidelOrtho Corporation CFO transition: Micah Young to succeed Joseph M. Buskyeffective July 6, 2026 · 8-K filed June 23, 2026 · sec.gov, Item 5.02
2026-02-1910-K signature
Joseph M. Busky signed the annual report as Chief Financial Officer (Principal Financial and Accounting Officer)
10-K filed February 19, 2026 · sec.gov
“/s/ J OSEPH M. B USKY Chief Financial Officer (Principal Financial and Accounting Officer)”
Company
| Ticker | QDEL |
|---|---|
| SEC CIK | 0001906324 |
| Industry (SIC) | In Vitro & In Vivo Diagnostic Substances (2835) |
| Roster note | The DEF 14A filed 2026-04-27 also names Joseph M. Busky alongside a Chief Financial Officer title. An 8-K with Item 5.02 was filed on 2026-06-23, after this 10-K; any CFO change it reports is tracked on the moves record. |
Same industry on the record
2Other companies the roster files under SIC “In Vitro & In Vivo Diagnostic Substances”.
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.